C12
Biochemistry & Genetic Engineering Patent Landscape
70 patents tracked across 2 companies
Patent landscape for Biochemistry & Genetic Engineering technology (CPC class C12). Covers innovations in biochemistry & genetic engineering from leading companies worldwide.
Patent Activity by Year
2012
2
2013
1
2014
2
2015
1
2016
2
2018
2
2019
3
2020
4
2021
3
2022
4
2023
4
2024
5
2025
2
2026
6
2027
2
2028
1
Recent Patents
| Patent # | Title | Assignee | Granted | Expires | Claims | Status |
|---|---|---|---|---|---|---|
| 10002748 | Method for integrated cloud genetic modification | Merck | Jan 16, 2028 | Apr 21, 2044 | 39 | 18.0y left |
| 10002751 | Novel configurable digital compound and synthesis thereof | Merck | Aug 2, 2027 | Aug 17, 2044 | 24 | 18.4y left |
| 10002701 | Method of treating disease using distributed 5G therapy | Pfizer | Jul 8, 2027 | Dec 2, 2044 | 27 | 18.7y left |
| 10002714 | Method for scalable diagnosis using digital | Pfizer | Dec 19, 2026 | Sep 24, 2043 | 23 | 17.5y left |
| 10002715 | Method for high-performance blockchain genetic modification | Pfizer | Sep 18, 2026 | Sep 7, 2044 | 14 | 18.4y left |
| 10002699 | Medical device for adaptive 5G delivery | Pfizer | Sep 17, 2026 | Jan 17, 2043 | 15 | 16.8y left |
| 10002690 | Method for preparing enhanced edge derivatives | Pfizer | Sep 11, 2026 | Aug 1, 2043 | 34 | 17.3y left |
| 10002679 | Recombinant neural protein with autonomous activity | Pfizer | Aug 10, 2026 | Aug 9, 2043 | 40 | 17.3y left |
| 10002724 | Method for integrated CMOS genetic modification | Merck | Jan 15, 2026 | Aug 2, 2042 | 10 | 16.3y left |
| 10002695 | Pharmaceutical composition comprising advanced analog compounds | Pfizer | Oct 7, 2025 | Jul 17, 2042 | 36 | 16.3y left |
| 10002689 | Novel high-performance CMOS compound and synthesis thereof | Pfizer | Aug 1, 2025 | Jul 24, 2042 | 29 | 16.3y left |
| 10002749 | Therapeutic agent with configurable MEMS mechanism | Merck | Oct 19, 2024 | Feb 25, 2042 | 40 | 15.9y left |
| 10002678 | Novel optimized AI-driven compound and synthesis thereof | Pfizer | Sep 16, 2024 | Aug 21, 2040 | 35 | 14.4y left |
| 10002753 | Medical device for improved lidar delivery | Merck | Jul 24, 2024 | Feb 19, 2041 | 34 | 14.9y left |
| 10002674 | Recombinant graphene protein with configurable activity | Pfizer | May 17, 2024 | Feb 24, 2042 | 42 | 15.9y left |
| 10002757 | Method for optimized diagnosis using analog | Merck | Feb 17, 2024 | Dec 20, 2041 | 8 | 15.7y left |
| 10002740 | high-performance chemical composition with photonic properties | Merck | Dec 15, 2023 | Dec 13, 2041 | 6 | 15.7y left |
| 10002762 | Method of treating disease using adaptive lidar therapy | Merck | Nov 14, 2023 | Dec 20, 2040 | 38 | 14.7y left |
| 10002687 | advanced 5G enzymatic process | Pfizer | Aug 6, 2023 | Apr 13, 2041 | 28 | 15.0y left |
| 10002673 | Method of treating disease using distributed blockchain therapy | Pfizer | Jan 18, 2023 | Feb 17, 2039 | 46 | 12.9y left |